Precipio (STU:TGK) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TGK Precipio Inc STU:TGK
51 GF Score
Price €4.96
GF Value €2.26
! 2 Warning Signs
View Full Analysis

What is Precipio Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:TGK
51GF Score
Precipio Inc STU:TGK
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precipio (STU:TGK) Overvalued in 2026?

Based on GuruFocus' analysis, Precipio stock appears to be overvalued. The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.

Key valuation signals for STU:TGK:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precipio Business Description

Other Exchanges PRPO:USA
Address 4 Science Park, 3rd Floor, New Haven, CT, USA, 06511
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score

Get the complete analysis for STU:TGK

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.96
Price
€2.26
GF Value